FDA Clears Path for Generic METHERGINE Injections Sans Safety Worries
Published Date: 3/18/2026
Notice
Summary
The FDA has decided that METHERGINE injection wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they meet all the rules. Patients and healthcare providers can expect more affordable options soon, with no delays caused by safety concerns.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Generics Can Apply to Sell METHERGINE
The FDA determined on March 18, 2026 that METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, was not withdrawn for reasons of safety or effectiveness. This allows manufacturers to submit abbreviated new drug applications (ANDAs) that refer to this listed drug and may be approved if they meet all other legal and regulatory requirements.
Patients May See Lower-Cost Options Soon
Because the FDA found on March 18, 2026 that METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, was not withdrawn for safety or effectiveness, generic versions may be approved. Patients and health care providers who use this drug can expect more affordable generic options to become available if ANDA applicants meet approval requirements.
ANDA Applicants May Need Updated Labeling
The FDA said it will continue to list METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, in the Orange Book's Discontinued Drug Product List but noted that if the Agency determines the drug's labeling should be revised to meet current standards, it will advise ANDA applicants to submit updated labeling. ANDA applicants may therefore need to prepare revised labeling if requested by FDA.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2026-05308, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V BROADWAY GIRL
The government is asking for your thoughts on letting a foreign-built small passenger boat, the M/V BROADWAY GIRL, operate in U.S. coastal waters carrying up to 12 paying passengers. This decision could affect U.S. boat builders and businesses that use American-made vessels. If you want to share your opinion, make sure to comment by April 17, 2026!
Next: 2026-05310, Certain Chocolate Milk Powder and Packaging Thereof; Issuance of Civil Penalties and Termination of Enforcement Proceeding
Four California companies got hit with big fines—totaling over $5 million—for breaking rules about certain chocolate milk powder and its packaging. These penalties cover violations lasting from 2 to 18 days, and the enforcement case is now officially closed. If you’re in the chocolate milk biz, this is a clear message: follow the rules or pay up!